Hannah Jacobs

Hannah Jacobs

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2024 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
HJHannah Jacobs
Hannah Jacobs
JSJonathan H. Soslow
Jonathan H. Soslow
MCMatthew D. Cornicelli
Matthew D. Cornicelli
SMShae A. Merves
Shae A. Merves
RGRuchira Garg
Ruchira Garg
Jason Nathaniel JohnsonJason Nathaniel Johnson
Jason Nathaniel Johnson
Cardiovascular magnetic resonance (CMR) is used to diagnose myocarditis in adults and children based on the original Lake Louise criteria (LLC) and more recently the revised LLC. The major change included in the revised LLC was the incorporation of parametric mapping, which significantly increases the sensitivity and specificity of diagnosis. Subsequently, scientific statements have recommended the use of parametric mapping in the diagnosis of myocarditis in children. However, there are some challenges to parametric mapping that are unique to the pediatric population. Our goal is to characterize clinical CMR and parametric mapping practice patterns for the diagnosis of myocarditis in pediatric centers. The Cardiovascular Magnetic Resonance Evaluation in Return to Athletes for Myocarditis in Coronavirus Disease 2019 and Immunization Consortium (CERAMICi) created a Research Electronic Data Capture (REDCap) survey to evaluate clinical practice patterns for diagnosis of myocarditis in pediatrics. This survey was distributed to the Society for Cardiovascular Magnetic Resonance community. Fifty-nine responses from 51 centers were received, with only one response from each center being utilized. Only 35% (18/51) of centers (37% (14/38) North America, 31% (4/13) international) reported using CMR routinely in all patients with a suspicion of myocarditis. Diagnostic uncertainty was noted as the most important reason for CMR, while cost was noted as the least important consideration. The majority of centers reported using the revised LLC (37/51, 72%) compared to original LLC (7/51, 14%) or a hybrid criteria (6/51, 12%). When looking at the use of parametric mapping, only 5/47 (11%) for T1 mapping and 11/49 (22%) for T2 mapping reported having scanner-specific pediatric normative data. Routine CMR imaging for diagnosis of myocarditis in pediatrics is infrequently performed at surveyed centers despite the focus on a group of non-invasive cardiac imagers. While the majority reported using parametric mapping, few centers reported having pediatric scanner-specific normative data. This highlights an important gap in the utilization of CMR that may aid in the diagnosis of myocardial disease.

9 June 2025 in Pediatric Radiology
Verified
Journal Article
Open access
PDF file
Jason Nathaniel JohnsonJason Nathaniel Johnson
Jason Nathaniel Johnson
TBTiffany L. Berthod
Tiffany L. Berthod
XCXiaoying Cai
Xiaoying Cai
MCM. Jay Campbell
M. Jay Campbell
ADAnudeep Dodeja
Anudeep Dodeja
OTOlga H. Toro-Salazar
Olga H. Toro-Salazar
A dedicated guideline to the evaluation of cardiovascular toxicity in pediatric cancer by cardiac magnetic resonance imaging (MRI) does not exist. Therefore, the aim of this document is to provide guidance in the utility, acquisition, and interpretation of cardiac MRI in childhood cancer survivors. We will focus on briefly defining cardiovascular toxicity in childhood cancer survivors and reviewing the key aspects of a detailed cardiac MRI study in a patient with acute versus chronic cardiovascular toxicity. We intend for this document to serve as a guideline on how to perform a cardiac MRI to evaluate cardiac toxicity based on a review of the current literature. There will be a review of a detailed cardiac MRI protocol (bi-ventricular volumes and mass, myocardial strain, tissue characterization, late gadolinium enhancement, and 4 Dimensional/4D flow) in the assessment of cardiovascular toxicity from cancer therapy. It is hoped that the availability of a standardized approach to cardiac MRI assessment in childhood cancer survivors improves cardiovascular care in this population. Graphical Abstract

3 November 2026 in Pediatric Cardiology
Verified
Journal Article
Open access
PDF file
CIChukwuemeka Igwe
Chukwuemeka Igwe
IKIsaac Kistler
Isaac Kistler
CSChristopher Schmitt
Christopher Schmitt
CAChance Alvarado
Chance Alvarado
SCSusan Creary
Susan Creary
HJHannah Jacobs
Hannah Jacobs
Sickle cell disease (SCD) encompasses a spectrum of genotypes, most commonly Hemoglobin (Hgb)SS and HgbSC. Diastolic dysfunction (DD) is common in SCD and impacts morbidity and mortality. We sought to evaluate if the rates of DD differed by SCD genotype and by hydroxyurea (HU) use among youths. This was a retrospective study of patients with HgbSS and HgbSC who received an echocardiogram, stratifying genotype and HU use. DD was assessed using mitral valve (MV) E/A ratio < 0.8 or > 2, septal E’ < 7 cm/s, lateral E’ 10; and LA: Aortic root (LA: Ao) ratio > 1.3:1. DD was defined as a diastolic aggregate score ≥ 2 of 5. Multivariable regression models adjusted for age were used to estimate the associations of DD with HU use by genotype. 39% of youth with SCD who had an echocardiogram had DD. DD rates were lower in those on HU ( n = 102, 36%) vs. those not on HU ( n = 94, 41%). Adjusting for age, youths with HgbSS on HU had lower odds of DD compared to those not on HU, OR 0.22 [95% CI (0.07, 0.59), p = 0.004]. Conversely, youth with HgbSC on HU had slightly increased odds of DD compared to those not on HU, OR 1.36 [95% CI (0.35, 4.98) p = 0.6]. In contrast to previous studies suggesting HU has no impact in reducing DD over time, our study showed DD was less common among patients with HgbSS on HU. Larger, prospective, multi-center studies are needed to assess longitudinal improvement of DD from baseline for SCD patients on HU.

12 September 2021 in Echocardiography
Verified
Journal Article
Closed access
PDF file
HJHannah Jacobs
Hannah Jacobs
JAJulie B. Aldrich
Julie B. Aldrich
MDMarc Dutro
Marc Dutro
SLSimon Lee
Simon Lee
DRDaniel G. Rowland
Daniel G. Rowland
CCClifford L. Cua
Clifford L. Cua

Verified
Journal Article
Open access
PDF file
MMMacala Maney
Macala Maney
CRCarson Richardson
Carson Richardson
IKIsaac Kistler
Isaac Kistler
SFSamantha Fichtner
Samantha Fichtner
HJHannah Jacobs
Hannah Jacobs
CCClifford L. Cua
Clifford L. Cua
Background: Ventricular septal defects (VSD) are the most common form of congenital heart disease (CHD). Current guidelines recommend surveillance transthoracic echocardiograms (TTE) following surgical closure of perimembranous VSDs (pVSD); however, duration of screening is not explicitly stated. The goal of this study is to determine the utility of follow-up TTEs after uncomplicated pVSD surgical closure. Methods: Single-site retrospective analysis was conducted on patients who underwent pVSD surgical closure. Patients were excluded if diagnosed with other CHD, had complications 1 year post-repair, or lacked data 1 year post-repair. Serial TTEs were reviewed. A Kaplan–Meier curve was used to illustrate the 5-year complication-free survival. Results: A total of 117 patients met inclusion criteria. A 97% 5-year complication-free survival was observed. Four patients had complications >1 year post-repair: one non-obstructive subaortic ridge, one pulmonary vein stenosis, one pinhole residual pVSD, and one ventricular ectopy with ventricular dysfunction. Of the 113 complication-free patients, 197 TTEs were performed with no change in clinical management. Conclusions: Beyond 1 year post-repair, the occurrence of new complications following uncomplicated pVSD surgical closure is rare. Unless clinical concerns arise, the utility of routine TTEs > 1 year post-repair in this uncomplicated post-surgical cohort should be reassessed. Larger multicenter studies are needed to determine the utility of routine TTEs.